NTC
HZNP

North Tide Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

North Tide Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-692,700
Closed -$10.2M – 16
2017
Q1 		$10.2M Buy
+692,700
New +$11.2M 1.57% 12

Other funds holding HZNP

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

North Tide Capital's HZNP Position: Q2 2017 in Review

North Tide Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 692,700 shares — an estimated $10.2M sold.

North Tide Capital first reported a position in HZNP in Q1 2017 and held it in 1 quarter. The position peaked at $10.2M in Q1 2017. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

  • North Tide Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • North Tide Capital sold 692,700 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $10.2M.
  • North Tide Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017 and held it in 1 quarter.
  • North Tide Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $10.2M in Q1 2017.
  • 190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on North Tide Capital's 13F filing for Q2 2017, filed 14 Aug 2017.